Study Provides Technology Insights to Improve Patient Engagement
A Greenphire study of 600 clinical trial professionals from various stakeholders weigh in on emerging patient engagement trends
Greenphire has released its global 2023 State of Clinical Trial Patient Convenience Market Trends survey, providing insights from 600 clinical trial sites, sponsors, and CRO personnel are responding to emerging trends for patient engagement.
Key highlights include:
Patient Tech Accessibility – 90% of sponsors and 86% of sites agree that it is important for participants in a clinical trial to have access to the study information digitally via web or mobile applications (such as a phone or tablet).
44% of sponsors agree that having the opportunity to complete a participant experience survey in order to gain insights on feedback is very important.
Financial Accessibility – 93% of sites and sponsors agree that ensuring study volunteers, both with and without bank accounts, can be easily reimbursed for out-of-pocket expenses.
Location Accessibility – 90% of sites and 95% of sponsors agree that removing financial and logistical barriers from patient participation in clinical trials can improve retention.
The full survey results are available for free download.
Reference: New Greenphire Study Finds Unified Technology Essential for Enhancing Patient Experience and Engagement in Clinical Trials. KING OF PRUSSIA, Pa., July 12, 2023.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
HHS Cancels Moderna Grant for Late-Stage Development of mRNA Vaccine Candidate
June 4th 2025Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s award for almost $600 million to accelerate vaccine development will be terminated.
